Clinical Trials Logo

Clinical Trial Summary

Investigate whether ranolazine, a novel anti-anginal agent with antiarrhythmic properties, has a role in the management of symptomatic ventricular premature beats.


Clinical Trial Description

The main objective is to compare the effect of ranolazine versus placebo on premature ventricular beats (using 24-hour ambulatory electrocardiographic monitoring) for subjects with symptomatic palpitations. Subject population will consist of seventy-two adult subjects of both sexes who have greater than 1,000 premature ventricular beats during initial monitoring. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01996618
Study type Interventional
Source Walter Reed National Military Medical Center
Contact Michael S Cahill, MD
Phone 301-295-0394
Email michael.s.cahill.mil@health.mil
Status Recruiting
Phase Phase 4
Start date January 2014
Completion date July 2016